Anixa Biosciences, Inc.

ANIX

US03528H1095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 22/05/2024 BST			5-day change	1st Jan Change
2.6 ^USD	-4.76%		-11.26%	-32.99%

05-08	Anixa Biosciences, Inc. Enters into a Joint Development Agreement with Cleveland Clinic to Develop Novel Vaccines for Various Cancer Types	CI
04-18	Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board	CI

ITUS Corporation Appoints Amit Kumar to American Cancer Society National Board of Directors

November 30, 2016 at 01:16 pm

ITUS Corporation announced that Dr. Amit Kumar, the company's Executive Chairman, has been appointed to serve on the National Board of Directors of the American Cancer Society.

Latest news about Anixa Biosciences, Inc.

Anixa Biosciences, Inc. Enters into a Joint Development Agreement with Cleveland Clinic to Develop Novel Vaccines for Various Cancer Types	05-08	CI
Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board	04-18	CI
Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	03-12	CI
Anixa Biosciences Initiates Higher Dosing in Phase 1 Study of Ovarian Cancer Treatment	02-12	MT
Anixa Biosciences Says Japan Grants Patent to Ovarian Cancer Vaccine Technology	01-23	MT
Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology	01-23	CI
North American Morning Briefing : Stock Futures Steady as Earnings Season Ramps Up	01-23	DJ
Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	01-16	CI
North American Morning Briefing : Stock Futures -2-	01-16	DJ
North American Morning Briefing : Samsung Warning Knocks Tech Stocks	01-09	DJ
North American Morning Briefing : Stock Futures Struggle After Weak China Data	01-02	DJ
Anixa Biosciences Unveils 'Positive' Results From Phase 1 Trial of Breast Cancer Vaccine	12-07	MT
Transcript : Anixa Biosciences, Inc. - Special Call	12-06
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine	12-06	CI
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology	11-27	CI
Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board	23/10/23	CI
Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial	13/10/23	CI
Anixa Biosciences, Inc. Establishes Cancer Business Advisory Board	19/09/23	CI
Anixa Biosciences, Inc.(NasdaqCM:ANIX) added to S&P Global BMI Index	18/09/23	CI
North American Morning Briefing : Concerns About -2-	07/09/23	DJ
Anixa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	06/09/23	CI
Anixa Biosciences Starts Treatment of Third Patient in Clinical Trial of Ovarian Cancer Therapy; Shares Rise	28/08/23	MT
Anixa Biosciences Says Cleveland Clinic Enrolling Patients for Study of Cancer Vaccine Plus Keytruda	07/08/23	MT
Anixa Biosciences, Inc. Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial	07/08/23	CI
Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology	27/07/23	CI

Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Companyâs vaccine portfolio consists of technology focused on the immunization against specific retired proteins.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.6 USD

Average target price

12 USD

Spread / Average Target

+361.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ANIXA BIOSCIENCES, INC.	-32.99%	82.94M
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+44.87%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B

Other Biotechnology & Medical Research

Anixa Biosciences, Inc.

Equities

ANIX

US03528H1095

Biotechnology & Medical Research

ITUS Corporation Appoints Amit Kumar to American Cancer Society National Board of Directors

Latest news about Anixa Biosciences, Inc.

Chart Anixa Biosciences, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research